Tirzepatide & HFpEF Research: NEJM Trial Findings
An NEJM RCT in 731 obese HFpEF patients found tirzepatide reduced cardiovascular events and improved quality-of-life scores versus placebo.
An NEJM RCT in 731 obese HFpEF patients found tirzepatide reduced cardiovascular events and improved quality-of-life scores versus placebo.